Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain McInnes

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
BMC Rheumatology|July 19, 2021
BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort studyFiona Rayner, Amy E Anderson, Kenneth F Baker, et al.
Annals of the Rheumatic Diseases|October 8, 2013
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)Maxime Dougados, Martin Soubrier, Anna Antunez, et al.
Annals of the Rheumatic Diseases|March 11, 2010
Treating rheumatoid arthritis to target: recommendations of an international task forceJosef S Smolen, Daniel Aletaha, Johannes W J Bijlsma, et al.
Annals of the Rheumatic Diseases|February 6, 2021
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19Alessia Alunno, Aurélie Najm, Pedro M Machado, et al.
Annals of the Rheumatic Diseases|March 18, 2019
Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patientsFrances Humby, Myles Lewis, Nandhini Ramamoorthi, et al.
Annals of the Rheumatic Diseases|November 7, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statementPeter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases|March 4, 2025
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 updatePeter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Annals of the Rheumatic Diseases|May 22, 2020
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 updateLaure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases|May 7, 2010
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
The Lancet. Rheumatology|January 22, 2024
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trialsFelice Rivellese, Alessandra Nerviani, Giovanni Giorli, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
BMC Rheumatology|July 19, 2021
BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort studyFiona Rayner, Amy E Anderson, Kenneth F Baker, et al.
Annals of the Rheumatic Diseases|October 8, 2013
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)Maxime Dougados, Martin Soubrier, Anna Antunez, et al.
Annals of the Rheumatic Diseases|March 11, 2010
Treating rheumatoid arthritis to target: recommendations of an international task forceJosef S Smolen, Daniel Aletaha, Johannes W J Bijlsma, et al.
Annals of the Rheumatic Diseases|February 6, 2021
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19Alessia Alunno, Aurélie Najm, Pedro M Machado, et al.
Annals of the Rheumatic Diseases|March 18, 2019
Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patientsFrances Humby, Myles Lewis, Nandhini Ramamoorthi, et al.
Annals of the Rheumatic Diseases|November 7, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statementPeter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases|March 4, 2025
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 updatePeter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Annals of the Rheumatic Diseases|May 22, 2020
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 updateLaure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases|May 7, 2010
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
The Lancet. Rheumatology|January 22, 2024
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trialsFelice Rivellese, Alessandra Nerviani, Giovanni Giorli, et al.
Pageof 6